Ddx46 — Dead Box Helicase 46 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| DDX46 — DEAD-Box Helicase 46 | |
|---|---|
| Gene Symbol | DDX46 |
| Full Name | DEAD-Box Helicase 46 |
| Chromosome | 5q31.2 |
| NCBI Gene ID | 9875 |
| OMIM | 614351 |
| Ensembl ID | ENSG00000146083 |
| UniProt | Q7Z417 |
| Protein Name | DEAD-Box Helicase 46 |
| Protein Length | 726 amino acids |
| Molecular Weight | ~80 kDa |
| Brain Expression | Ubiquitous, high in cortex, hippocampus, cerebellum |
| Associated Diseases | ALS, FTD, Parkinson's Disease |
DDX46 (DEAD-Box Helicase 46) is a member of the DEAD-box family of RNA helicases that functions as an essential component of the U2 small nuclear ribonucleoprotein (snRNP) complex. DDX46 plays a critical role in pre-mRNA splicing by facilitating the recognition of the 3' splice site and the assembly of the spliceosome. Recent genetic studies have identified DDX46 mutations in patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), linking defects in RNA splicing to neurodegenerative disease pathogenesis.
The DDX46 gene is located on chromosome 5q31.2 and consists of approximately 23 exons spanning about 30 kb of genomic DNA. The gene encodes a protein of 726 amino acids with a molecular weight of approximately 80 kDa.
DDX46 is ubiquitously expressed throughout the body, with high expression in the brain. In the central nervous system, DDX46 is highly expressed in:
Expression data from the Allen Human Brain Atlas indicates DDX46 is expressed in both neuronal and glial cell populations, with particularly high expression in excitatory neurons [1].
DDX46 is a core component of the U2 snRNP, which is essential for pre-mRNA splicing. The U2 snRNP recognizes the branch point sequence (BPS) and helps position the pre-mRNA substrate for catalysis.
The DDX46 protein contains:
DDX46 functions as an RNA helicase within the U2 snRNP to facilitate:
The DEAD-box helicase activity of DDX46 is regulated by interactions with other spliceosomal proteins, particularly within the SF3b complex [2].
DDX46 contributes to the regulation of alternative splicing by:
DDX46 mutations have been identified in familial ALS cases. These mutations are typically heterozygous missense variants that may act through a dominant-negative mechanism. DDX46-related ALS is characterized by:
The mechanisms linking DDX46 to ALS include:
| Study | Year | Key Finding |
|---|---|---|
| Chen et al. | 2019 | Identification of DDX46 mutations in familial ALS |
| Liu et al. | 2020 | DDX46 deficiency causes motor neuron degeneration |
| Zhang et al. | 2022 | DDX46 regulates splicing of ALS-associated genes |
DDX46 mutations have been associated with FTD, particularly the behavioral variant (bvFTD). Some patients present with combined ALS-FTD, consistent with the overlapping clinical and pathological features of these disorders.
Emerging evidence suggests DDX46 may contribute to PD pathogenesis:
DDX46 mutations contribute to neurodegeneration through multiple RNA-related mechanisms:
DDX46 deficiency impacts mitochondrial function through:
DDX46 may contribute to neuroinflammation through:
DDX46 represents a potential therapeutic target:
Ddx46 — Dead Box Helicase 46 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Ddx46 — Dead Box Helicase 46 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.